Biosimilars are biological medicinal products that are highly similar, but not identical, to an already authorized reference biologic.
Unlike small-molecule generics, biosimilars are produced in living systems, and even minor changes in manufacturing processes can affect their quality, safety, or immunogenicity.
As a result, pharmacovigilance for biosimilars focuses not only on detecting known adverse reactions but also on identifying rare, delayed, or immunologically mediated events that may not be fully characterized during pre-approval clinical trials.
These trials are typically smaller than those conducted for originator biologics and are designed to demonstrate biosimilarity rather than independently establish safety and efficacy across all indications.
A central element of biosimilar pharmacovigilance is traceability 🔦 . Accurate identification of the specific product administered—including brand name, manufacturer, and batch or lot number—is essential when reporting adverse events. Regulatory agencies therefore emphasize the use of distinct brand names and encourage batch-level reporting in spontaneous adverse event systems.
Immunogenicity monitoring 💡 is another cornerstone of biosimilar PV. All biologics, including biosimilars and their reference products, have the potential to induce anti-drug antibodies, which may reduce efficacy or cause adverse reactions such as hypersensitivity or loss of response. Risk management plans (RMPs) typically include immunogenicity monitoring strategies, registries, or post-authorization safety studies.
Regulatory authorities such as the FDA and EMA require biosimilar manufacturers to implement comprehensive pharmacovigilance systems equivalent to those of originator companies. These systems include routine signal detection, periodic safety update reports, and continuous benefit–risk evaluation. Importantly, pharmacovigilance responsibilities extend beyond manufacturers to healthcare professionals, pharmacists, and patients, all of whom play a role in reporting adverse events accurately and promptly.
In conclusion, pharmacovigilance for biosimilars is essential to ensure their safe and effective use in clinical practice. Through robust traceability, immunogenicity monitoring, post-marketing studies, and stakeholder engagement, PV systems help sustain trust in biosimilars and support their expanding role in improving patient access to biologic therapies worldwide.
To learn more from related topics, please visit our website or newsletter at https://medipharmsolutions.com/newsletter/
No Comments